Kolexia
Swalduz Aurelie Pneumologie
Swalduz Aurelie
Pneumologie
Centre Léon-Bérard
Lyon, France
210 Activités
485 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire non à petites cellules Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinomes Adénocarcinome pulmonaire Adénocarcinome Métastase tumorale COVID-19 Carcinogenèse

Collaborateurs

Voir plus
Perol Maurice
Perol Maurice
Centre Léon-Bérard, Lyon, France
Decroisette Chantal
Decroisette Chantal
Centre Léon-Bérard, Lyon, France
Avrillon Virginie
Avrillon Virginie
Centre Léon-Bérard, Lyon, France
Greillier Laurent
Greillier Laurent
Hôpital Nord Marseille, Marseille, France

Industries

Voir plus
AstraZeneca
37 collaboration(s)
Dernière en 2023
Janssen
22 collaboration(s)
Dernière en 2023
Edimark
14 collaboration(s)
Dernière en 2023
Amgen
9 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours: A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Essai Clinique (DeuterOncology)   13 mars 2024
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
Essai Clinique (Nuvalent Inc.)   07 mars 2024
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK): A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   06 mars 2024
Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Therapeutic advances in medical oncology   06 mars 2024
HER2: A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Essai Clinique (Enliven Therapeutics)   01 mars 2024
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1): A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Essai Clinique (Nuvalent Inc.)   31 janvier 2024
Survival of bronchopulmonary cancers according to radon exposure.
Frontiers in public health   24 janvier 2024
Efficacité et tolérance du sotarasib chez les patients porteurs d’un cancer bronchique non à petites cellules avec une mutation KRAS G12 C : résultats de l’étude en vie réelle IFCT-2102 Lung KG12Ci
28e Congrès de Pneumologie de Langue Française   01 janvier 2024
AMPHISARC: A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)
Essai Clinique (Centre Léon-Bérard)   06 décembre 2023
Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors
Abstracts: 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved   01 décembre 2023